In today’s briefing:
- FleetPartners (FPR AU): Approaching the Endgame with Materially Higher Revised Offers
- Abacus Group (ABG AU): Charter Hall Ups Stake As Share Price Ekes Out New Lows
- Abacus Group (ABG AU): Synthetic Expert Call Transcript (15 Sep 2026)
- ADX Energy (ASX: ADX): Industry partner for GOLD cluster
- Artrya (ASX:AYA): Share price dragged down by EchoIQ FDA denial; AYA joins S&P/ASX 300; Scenario test the robustness of our forecasts maintain $6.07 per share valuation
- IREN’s $25 Billion–$30 Billion Expansion — Can Contracted ARR Keep Pace?
- Omniscient Neurotechnology Pty Limited
FleetPartners (FPR AU): Approaching the Endgame with Materially Higher Revised Offers
- FleetPartners Group (FPR AU) has disclosed that SG Fleet, Orix Corp (8591 JP) and Sumitomo Corp (8053 JP) have revised their NBIOs to A$4.55, A$4.65 and A$4.65, respectively.
- Element Fleet Management (EFN CN) has dropped out. Sg Fleet (SGF AU) is also likely to drop out, as its revised offer already factors in substantial synergies.
- One of the Japanese strategics will win, as FleetPartners is a relatively small, strategically adjacent bolt-on. A final binding offer around A$4.90-A$5.00 per share is possible.
Abacus Group (ABG AU): Charter Hall Ups Stake As Share Price Ekes Out New Lows
- Back on the 4th February 2026, Abacus Group (ABG AU) announced preliminary discussions with 19.7%-held Abacus Storage King (ASK AU) concering the potential internalisation of ASK’s management functions.
- A binding agreement followed in May and completion on the 1st July. ASK (now known as storage King Group [SKG]) was subsequently reclassified as a financial investment.
- In April this year, Charter Hall (CHC AU) announced a 5.837% stake. Ahead of Abacus’ FY26 results, Charter Gall bumped to 7.04%. Abacus is currently trading at a decade-plus low.
Abacus Group (ABG AU): Synthetic Expert Call Transcript (15 Sep 2026)
- Abacus Storage King’s (now Storage King Group, ASX: SKG) internalisation completed on June 30, 2026, represents a structural loss of high-margin recurring fee streams for Abacus Group (ASX: ABG), offset only by a modest $24.0 million cash payment. While the transaction is 6.0% accretive to SKG’s Funds From Operations (FFO) due to $7.0 million in annual fee savings, it leaves ABG as a pure-play commercial landlord holding a highly illiquid 19.8% passive stake in SKG (valued at approximately $340.0 million). This stake now represents roughly 40% of ABG’s entire $809.0 million market capitalisation, illustrating the deep discount the market is applying to ABG’s core office portfolio.
- Charter Hall’s (ASX: CHC) creeping stake in ABG—which was recently increased to 7.04%—is a highly calculated strategic play on ABG’s deep valuation discount. Given that ABG trades at a 46% discount to its $1.73 Net Tangible Assets (NTA), Charter Hall is positioning itself for either a cheap, opportunistic buyout or a forced asset play to seize full control of key co-owned premium assets, specifically the 201 Elizabeth Street office tower in Sydney.
- ABG’s management has historically prioritized Asset Under Management (AUM) accumulation over Net Asset Value (NAV) growth, leaving the group exposed to severe capital recycling bottlenecks. The transition of the core head trusts (Abacus Trust and Abacus Income Trust) to Managed Investment Trust (MIT) status on July 1, 2025, was a delayed but necessary regulatory fix to lower withholding tax for foreign capital. However, severe local development approval bottlenecks of 18 to 24 months continue to stall SKG’s 101,000 square metre development pipeline, capping organic growth velocity.
Disclaimer: The following transcripts are synthetic, AI-generated on demand, and compiled exclusively from public data sources; no real-word experts were actually interviewed. This content is designed to highlight potential market mispricings, explore compelling lines of inquiry, and suggest strategic questions rather than present verified facts. All specific financial metrics and data points, including market shares, TAM, margins, and growth rates, are AI-estimated approximations. They may be inaccurate and must be independently verified.
ADX Energy (ASX: ADX): Industry partner for GOLD cluster
- Empyrean Energy has signed a binding Heads of Agreement to acquire a 10% economic interest in the GOLD Cluster Area in Austria, in exchange for funding the drilling and testing of the GOLD‑1 well.
- The required investment is EUR 555,400.
- Empyrean will also pay EUR 50,000 (non‑refundable) for an exclusivity period running until 16 October, during which final funding arrangements and documentation will be completed.
Artrya (ASX:AYA): Share price dragged down by EchoIQ FDA denial; AYA joins S&P/ASX 300; Scenario test the robustness of our forecasts maintain $6.07 per share valuation
- Artrya fell -21% last week and at one point, was down another -8% today.
- At today’s close, the shares are down -50% from their all-time high of $6.49 set just three months ago on the 6th July.
- The pullback is partly a result of disappointing 4Q26 results (see ‘Valuation downgrade but market overreaction is a buying opportunity’) compounded by 1) last Tuesday’s rejection by the FDA of EchoIQ’s EchoSolv HF submission; and 2) the ongoing delay in Salix Coronary Flow FDA submission.
IREN’s $25 Billion–$30 Billion Expansion — Can Contracted ARR Keep Pace?
- The full fiscal year 2026 results update from IREN presents a company focused on addressing structural constraints in the AI infrastructure ecosystem, particularly on the physical infrastructure side encompassing data centers, power, and land.
- IREN operates across three integrated layers: physical data centers and supporting infrastructure; compute hardware such as GPUs and networking; and software and managed services, exemplified by its Mirantis division.
- This vertical integration aims to capture value across the stack and enhance the customer offering.
Omniscient Neurotechnology Pty Limited
- Omniscient secured its third FDA clearance. On September 11, Omniscient announced 510(k) clearance for its Quicktome Deep Brain (DB) workflow, extending its connectomic platform into deep brain stimulation.
- As discussed in our August report, Omniscient had identified DBS as the next platform extension, with a submission already filed and clearance expected by the end of 2026.
- The clearance arrived with a full quarter to spare.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
